The proposed bill, if enacted, would amend current statutes by appropriating $5,000,000 from the state General Fund for fiscal year 2026 to the Department of Health Services (DHS) specifically for conducting a certified clinical research study on the use of ibogaine for treating neurological diseases, including traumatic brain injury and post-traumatic stress disorder. This appropriation is a new insertion into the law, which would require DHS to award grants only to entities that meet specific criteria, such as having a proven history in neurological research and treatment, possessing adequate clinical and research facilities, and demonstrating a commitment to matching funds of at least $5,000,000 from non-state sources.

Additionally, the bill includes a provision that exempts the appropriation from lapsing, which is a significant change from current law. The existing statute does not contain this exemption, thus ensuring that the allocated funds remain available for the intended purpose without the risk of being returned to the state treasury at the end of the fiscal year. Overall, the bill aims to enhance research capabilities in Arizona regarding neurological diseases through targeted funding and specific eligibility requirements for grant recipients.